text:
Hi all,
I am trying to figure out if a user is doing something they shouldn't be. I started looking this morning when I went in our Server Room to restart a server. When I went to log in to the server the cached name for the last user was one of our sales people. None of them should have a key to the server room, or have need of access, let alone a reason to login to the server in that room. (The server in question is our Terminal Server that they do login to via RDP on their desktops.)
I looked at the event log to see if I could tell when the user had logged into that server locally, but did not see any logon events "Logon Type: 2", but I did notice that this user is the only one who is logging into the server at all hours of the night, and early morning. There are logon events for 11pm, and 02am, no one should be here at those times. The logons at those weird hours are from her IP address at her company workstation as well.
As far as I can tell so far there is no software that is calling to this server at those odd hours. Those events are not present for any other user.Am I being overly paranoid, or should I pursue this further. I am not really sure what to do next other than install monitoring software on the users workstation, after speaking with the boss.
14 Replies
Jun 5, 2012 at 1:57 UTC
I always love the "mystery" challenges..... makes me feel like a detective or spy or something ....
Anyway after reading your post, I can't help but wonder (and this might not even be applicable) if the user account in question, may have been written down (perhaps under their keyboard) where the cleaning staff may have found it, and use it to surf the net after hours......
If there is no legit reason for anyone to be logging in at those hours ..... you could consider using "logon hours".....
Jun 5, 2012 at 1:58 UTC
Have you noticed those same login times several days in a row? It's possible that there is some scheduled task that runs at certain times...but I don't know what they could be doing. This should be researched further.
Jun 5, 2012 at 2:01 UTC
Low tech = changing door lock.
Jun 5, 2012 at 2:13 UTC
I wonder if that would happen if the user remoted to the terminal server but turned on the "console" checkbox, or used the mstsc /admin command.
Either way I'd put some sort of logging in place...if you use login scripts you can have the script append the data/time/username to a text log file somewhere to prove they're definitely logging in and its not some other app.
I'd also check that user's computer for malware and do a netstat on it to see if there's any rogue connections going on. Last but not least...have them shut down at night to see if that changes anything.
Jun 5, 2012 at 2:15 UTC
Thanks for the replies so far. We do not have an overnight cleaning staff. The log shows that this has been going on with this user for at least the last 2 weeks. It may be a scheduled task. I am going to look into that further tonight.
The cached username at the local terminal in the server room though concerns me the most. only 6 people should have that key, 3 are the owners of the company, my boss, maintenace and myself. I will let you all know as I find out more. More suggestions are appreciated also.
Jun 5, 2012 at 2:21 UTC
I always love the "mystery" challenges..... makes me feel like a detective or spy or something ....
Anyway after reading your post, I can't help but wonder (and this might not even be applicable) if the user account in question, may have been written down (perhaps under their keyboard) where the cleaning staff may have found it, and use it to surf the net after hours......
If there is no legit reason for anyone to be logging in at those hours ..... you could consider using "logon hours".....
This... if you want to cathc the guys on the act use the refog employee monitor, even the demo would prove to be sufficient.
Jun 5, 2012 at 2:25 UTC
We had someone walking into the server room at night and leaving the door open...cause our servers to overheat in the summertime and shutdown. I put a small non working webcam up in the corner and put a sign up saying you are under surveillance. Never had the issue again.
I think people caught on to the fact it was cold up there and wanted to relax during their breaks.
You don't have a second shift like that obviously, but if people think they are being watched they will act accordingly. + its cheap
Jun 5, 2012 at 2:28 UTC
1st Post
Also changing of passwords on your server is a good idea when done on a weekly / monthly basis, also you high encryption passwords of 8 to 12 characters.
Jun 5, 2012 at 2:39 UTC
I created a batch file to track logon, and logoffs on the network. hopefully this will give me more info.
Jun 5, 2012 at 2:46 UTC
I looked at the user's scheduled tasks, and did not see anything that would be logging to the server after hours. Scheduling an AV scan for after COB now.
Jun 5, 2012 at 2:47 UTC
You can stop that using from logging on locally and remotely. Set the Log on Locally to only the users you choose. I forget where exactly, but you can do it in Group Policies.
Only the Domain Admins can log on to the server here.
Only admins should be allowed to log on locally or remotely.
You also restrict that user to certain computers in Active Directory under the Properties of their account.
Jun 5, 2012 at 2:58 UTC
I have the security configured as you suggested. The users are only allowed to login to this one server which is a terminal server used for a majority of their work.
Jun 5, 2012 at 3:31 UTC
i second the group policy-
under computer configuration
-Policies|windows settings|security settings|local policies| user rights assignments
turn on "Allow log on through terminal services" for your terminal (sales) users
then define the policy settings for "allow log on locally" and add your server administrators there
you can also limit the times they are allowed to login in AD, but since they are a sales person i dont think you want to discourage them from working.
Jun 6, 2012 at 10:00 UTC
Low tech = changing door lock.
And password (in case of something more nefarious)
This discussion has been inactive for over a year.
You may get a better answer to your question by starting a new discussion.


text:
Author Tags: Film
Born in Cairo, Egypt on July 19, 1960, internationally acknowledged film director Atom Egoyan arrived with his family in Victoria, B.C. at age two. Prior to emerging as a leading player in the Canadian film industry during the 1980s and 1990s, he made his first 8mm film called Lusts of an Eunuch while attending Mount Douglas Secondard School in Victoria. Egoyan's parents ran "Ego Interiors," a sophisticated furnishing store in Victoria in the late 1960s and 1970s.
His films have included Next of Kin, Family Viewing, Speaking Parts, The Adjustor, Exotica, The Sweet Hereafter, Felicia's Journey, Ararat and Calendar. Reportedly The Adjustor was inspired by arson that destroyed his mother's interior design business on Fort Street in Victoria. Also according to Ross Crockford's Victoria: The Unknown City, his murder-mystery Where the Truth Lies was influenced by his teenage stint as a houseboy [bellhop?] at the Empress Hotel. Egoyan received the Order of Canada in 1999.
With Ian Balfour, an associate professor in Toronto, Egoyan co-edited Subtitles: On the Foreigness of Film (Cambridge, Massachusetts: MIT Press, 2004).
[BCBW 2004] "Film"

subset: commoncrawl


text:
View Cart
Help | Contact
Pender's Music Co. offers a large selection of guitar, bass guitar, and folk instrument sheet music, as well as guitar method lesson books for every stage of your musical education. Select a guitar or folk category from the pull-down menu below to begin shopping.
Already know exactly what you need? Quickly add a product to your shopping cart by entering the Pender's item number:
Subscribe to E-News
Visit Our Staff Notes Blog
Our mobile website


text:
Home > Art / Photo > Photographs > Love is Serenity Today
Love is Serenity TodayReport abuse
More by this contributor
About this contributor
Join the DiscussionThis art/photo has 1 comment. Post your own now!
Savanah1111 said...
yesterday at 8:56 pm
yesterday at 8:56 pm
I love this. The rocks that form a heart. Creative!


text:
Qantas and Virgin Australia have no plans to cut the hefty fuel surcharges slugged on airline tickets despite steep falls in oil prices.
The airlines argue the 30 per cent slide in oil prices hasn't actually saved them much on their jet fuel bills.
Oil prices have slumped from around $US107 a barrel in July to around $US70 a barrel amid an oversupply in the market.
But Qantas says the price falls have shaved only $20 million off its $4.5 billion annual fuel bill.
Geoff Trotter, from monitoring group FuelTrac isn't buying it.
"The fuel surcharge should be at least 20 per cent lower based on the movement since July this year," he said.
"They are buying the fuel now really cheap, but their passengers are paying the same surcharge they paid when oil was $US112 a barrel."
Fuel price surcharges, which were introduced in 2004 amid a spike in oil prices, are a bigger deal for passengers than you might think.
Qantas customers booking a return economy trip the US are hit with a $680 surcharge, which is roughly a third of the cost of the ticket.
It also slugs passengers travelling to Europe, parts of Asia, and the Middle East, with the amounts depending on whether the ticket is for economy, premium economy, business or first class seats.
But the airline says the surcharges don't even cover its fuel bill.
"Fuel prices have more than doubled over the past decade and Qantas's current surcharges do not come anywhere close to recovering the cost of fuel to our bottom line," a spokesman said.
The airline says fuel prices will need to say low for a lot longer before it would consider cutting its surcharge.
"There would need to be a much more sustained and significant benefit before we would be in a position to revisit our surcharges," the spokesman said.
But Mr Trotter said the airline had lifted its fuel surcharge for US flights fourfold since 2004, while crude oil prices were only 33 per cent higher than a decade ago.
Virgin Australia imposes surcharges on flights to the US, Europe and the Middle East.
It says it works the fuel cost into the price of tickets on domestic routes, though it also says it has no savings to pass on to passengers from the lower oil price.
"Virgin Australia continually reviews its surcharges; however we have no changes to announce at present," the airline said in a statement to AAP.
"We look for a sustained trend in fuel price movements to increase or decrease our surcharges."


text:
Homepage with video
37.00$ / month
(when paid yearly)
Add to Cart
- Multiple platform
Windows, Mac, Linux...it's all good.
- rotoDRAW & rotoSNAP
A defining feature that will speed up your complex roto shots--there's nothing like it. Draw your first shape using your mouse or stylus. Then snap that shape to subsequent key frames by quickly tracing the shape.
- Intelligent Ripple Edit
The most intelligent Ripple Edit out there. Ripple Edit is great in theory, make minor tweaks and touches that are carried throuought your shot...but most fail in complex movement. Give ours a try and see how much time you will save.
- Interface
How much time do you spend looking at your software? How much does it suck to look at? We put a pretty dress on Flowbox, give 'er a spin.


text:
|Home | About | Journals | Submit | Contact Us | Français
VCL-AB01, a cationic lipid-formulated plasmid DNA (pDNA)-based vaccine that contains genes encoding genetically detoxified B. anthracis protective antigen (PA) and lethal factor (LF), was assessed in a Phase 1, dose-escalating clinical trial in healthy adults for safety and immunogenicity, and in nonhuman primates for immunogenicity and efficacy against challenge with a lethal dose of B. anthracis spores. Healthy 18—45 year old subjects were randomly assigned to receive either the investigational vaccine containing 0.2 mg, 0.6 mg, or 2 mg of total pDNA per dose, or saline placebo, administered at 0, 1 and 2 months. The 0.2 mg and 0.6 mg dose levels were generally well tolerated; however, dose-limiting reactogenicity was observed among subjects given the first 2 mg dose and the remaining 2 injections in the 2 mg group were reduced to 0.6 mg. Dose-related increases in seroconversion frequencies were observed. Overall, 10%, 33.3% and 80% of subjects in the 0.2, 0.6 and 2 mg groups, respectively, developed antibodies to PA and/or LF as measured by ELISA; however, antibodies with toxin neutralizing activity (TNA) were detected in only 1 subject. In monkeys that received a 0.6 mg dose 3 times at 2 week intervals, low levels of antibodies were detected by ELISA but not by the TNA assay in all animals just prior to challenge. Despite the absence of TNA, 3/4 animals survived the lethal challenge. In summary, VCL-AB01 was generally well tolerated in humans at a dose that provided immunity in monkeys despite the lack of robust TNA titers in either species.
Historically, Bacillus anthracis, the causative agent of anthrax, has been associated with herd animals and has not been commonly viewed as a significant human pathogen.1 However, with the realization that anthrax spores have been weaponized, anthrax has the potential to become a major human disease threat.2 Cases resulting from mailing of spores on the East Coast of the United States, as well as the outbreak in Sverdlovsk in the former Soviet Union, have demonstrated that B. anthracis spores can be produced inexpensively, are extremely stable when stored properly, and can be effectively distributed in populated areas.3 Mortality after infection with aerosolized anthrax spores (inhalational anthrax) has ranged from 40% to 90%.2,4 Consequently, B. anthracis spores are a likely organism for use as a bioterrorist weapon, and as such there is a real and present threat of an intentional and major outbreak of anthrax in humans.
Research on anthrax during the past several decades has provided information about the molecular basis of disease in humans, including the scientific basis for developing subunit vaccines.5 The virulence of B. anthracis is primarily the result of a multi-component toxin secreted by the organism. The protein toxins consist of three separate gene products, designated protective antigen (PA), lethal factor (LF) and edema factor (EF). LF and EF each bind to PA, resulting in the formation of lethal toxin (LT) and edema toxin (ET), respectively. The genes encoding these toxin components, along with the genes responsible for expression of the capsule, are required for full B. anthracis virulence. PA binds to the cell surface, where it undergoes cleavage resulting in the formation of a heptameric structure capable of delivering the toxins into the cell. LT is a zinc metalloprotease that cleaves several isoforms of mitogen-activated protein kinase and thereby disrupts signal transduction events within the cell eventually leading to cell death. ET is a calmodulin-dependent adenylate cyclase that causes deregulation of cellular metabolic events, leading to clinical manifestations that include edema. Protective antigen is an essential component of anthrax vaccines although other components may also contribute to immunity.5
The only anthrax vaccine licensed for use in the United States is Biothrax™ (also known as Anthrax Vaccine Adsorbed, or AVA), which is derived from vaccine candidates developed at Fort Detrick, Maryland in the 1950s. The licensed immunization regimen consists of 5 doses administered by the intramuscular route at 0 and 4 weeks and 6, 12 and 18 months, with annual boosters thereafter. The heightened public concern of deliberate, widespread anthrax exposure in the United States has resulted in a government call for an improved vaccine. Alternative vaccines that may offer improvements over Biothrax™ are under development, some of which are currently undergoing clinical testing, including recombinant PA (rPA)6,7 and plasmid DNA (pDNA)-based vaccine VCL-AB01 (Vical Incorporated, San Diego, CA) encoding genetically detoxified forms of PA and LF formulated with a cationic lipid-based DMRIE:DOPE adjuvant.8 Vaccination with anthrax PA protein-based vaccines or passive administration of anti-PA antibodies have conferred protection against lethal aerosol challenge with B. anthracis in mouse, rabbit, guinea pig and nonhuman primate models,9–14 providing evidence supporting a PA component for an anthrax vaccine. The plasmids used in VCL-AB01 have previously been shown to protect rabbits from aerosolized B. anthracis challenge.11
The objectives of these studies were three-fold: (1) to assess the safety of VCL-AB01 in a rabbit repeated dose toxicity study; (2) to assess the safety and immunogenicity of VCL-AB01 in a Phase 1, two-center, randomized, double-blind, placebo-controlled, dose-escalating clinical trial; and (3) to assess the immunogenicity and efficacy of VCL-AB01 in monkeys.
A repeated dose toxicity study was conducted in rabbits to assess the safety of repeated IM injections of VCL-AB01 on Days 0, 14, 28 and 56. No deaths occurred and no safety issues were associated with either the 2 mg or the 0.2 mg dose as determined by daily Draize scoring of the injection sites, daily clinical observations, body weights, food consumption, clinical chemistry, coagulation or ophthalmoscopic examination 48 hours and 4 weeks after the last injections. In addition, there was no evidence of production of anti-nuclear antibodies or antibodies to double stranded DNA (ds DNA).
Some inflammation at the injection site was observed microscopically. The severity of inflammation was not dose-dependent, but was associated with administration of both the low and high doses of VCL-AB01 as well as the high dose pDNA in phosphate-buffered saline (PBS). In all groups, the inflammation was reduced markedly over the recovery period and was not associated with injection site edema or erythema.
Some increases in spleen and kidney weights of animals (predominantly males) treated with VCL-AB01 and pDNA or PBS were noted but were not associated with any histological changes. These changes in spleens and in kidneys resolved over the 28-day recovery period.
Forty subjects were enrolled and received at least one dose of vaccine. The vaccine doses tested in each group and the demographics of the vaccinated subjects are shown in Table 1. Most of the subjects in Group A (0.2 mg dose) and Group C (2.0 mg dose) were males, while most of the subjects in Group B (0.6 mg dose) were females. The numbers of males and females were similar in Group D (placebo). The racial composition of Group A was spread across all of the racial groups while most of the subjects in the other three groups were white.
Three subjects discontinued the study early due to reasons unrelated to vaccination: two subjects in the 0.6 mg group (one withdrew; one was discontinued for noncompliance), and one subject in the 2 mg dose group (lost to follow-up). No deaths were reported during the study. Toxicity gradings of 3 and 4 were predetermined as serious adverse events (SAEs). Eight subjects experienced an SAE during the trial, three of which were considered vaccine-related grade 3 events: injection site pain, injection site reaction and headache. All vaccine-related grade 3 adverse events (AEs) occurred in subjects that received the 2 mg dose of vaccine. The occurrence of two grade 3 reactions (injection site pain) and systemic symptoms within 24 hours after the first injection among the 10 subjects given the first 2 mg dose of vaccine resulted in review of the safety data and a decision to dose de-escalate the 2 mg dose to 0.6 mg for subsequent doses for all subjects randomized to the 2 mg dose level. One subject given the first 0.6 mg dose in the 0.6 mg group developed grade 3 systolic hypertension 30 minutes after immunization, but the blood pressure was normal at the subsequent visit, and no further vaccinations were given. The remaining SAEs (social hospitalization, defined as having no place to go but in need of care; peritonsillar abscess; asymptomatic bradycardia; and a febrile syndrome) were not considered vaccine-related. There were no clinically important safety findings related to vaccination for any vaccine group with regard to clinical laboratory assessments, vital signs or physical examination findings.
The frequencies of injection site and systemic symptoms and signs recorded during the week following the first immunization are shown in Table 2. Most subjects given vaccine at any dose level experienced injection site discomfort, and dose-related increases in the frequencies of subjects who reported moderate to severe discomfort were observed (Table 2). Only one subject given placebo reported mild injection site discomfort after dose 2. Similar trends were observed after the second and third dose; although the overall frequencies were generally lower (Table 2). Two subjects discontinued the study early due to an AE in each of the groups given VCL-AB01; one subject in the placebo group also was discontinued from the study due to an AE. Most of the subjects who discontinued early from the study due to an AE had a vaccine-related AE that prompted the discontinuation.
In general, the frequencies and severities of systemic symptoms increased with increasing dose levels after the first dose of vaccine. The majority of subjects given the 2 mg dose level experienced fatigue and feverish sensations or chills, and many of these symptoms were characterized as moderate to severe. Systemic symptoms were somewhat less frequent and less severe after the second and third doses of 0.6 mg. Following the first injection, three subjects given the 2 mg dose reported fever, compared with zero and one in each of the other vaccine-recipient groups.
The frequencies of other injection site and/or systemic AE considered to be related to immunization increased in a dose-related fashion after the first dose of vaccine: 2, 1, 4 and 11 AEs were reported among 2, 1, 4 and 7 subjects in the placebo, 0.2 mg, 0.6 mg and 2 mg groups, respectively. Headache, the most common AE after the first dose, was reported by 0, 0, 1 and 5 subjects in the placebo, 0.2 mg, 0.6 mg and 2 mg groups, respectively. Myalgia and injection site swelling were reported in two subjects each after a 2 mg dose. From zero to two subjects in each group reported associated AEs after the second or third dose of vaccine.
Serologic responses were assessed before and after each immunization for anti-PA and anti-LF antibodies and for toxin neutralizing antibodies. The antibody concentrations of anti-PA IgG and anti-LF IgG were measured from serum samples collected at Day 0 and Weeks 6, 10, 28, 39 and 52. Table 3 shows the seroconversion frequencies, defined as the number of responders/total vaccinees at one or more time points after receiving at least one dose of VCL-AB01 or placebo. Overall comparisons among the three VCL-AB01 groups were significant for the number of subjects achieving anti-LF or anti-PA responses (p < 0.01); among pairwise comparisons, the 0.2 mg and 2/0.6/0.6 mg groups were significantly different (p = 0.0055) and the 0.6 mg and 2/0.6/0.6 mg groups trended toward significance (p = 0.0689).
Table 4 shows the number of subjects who seroconverted after 2 or 3 injections. Overall, 12/28 subjects (43%) who received ≥2 doses seroconverted following vaccination with VCL-AB01. A significant difference in overall seroconversion frequencies between the high and low dose groups (Fisher's exact test p = 0.0027) and a trend between high and middle dose groups (p = 0.154) were seen. A total of 8/10 subjects in the high dose group seroconverted to PA, LF, or both. No positive responses were observed among the 54 samples tested in each assay from the 9 placebo subjects except for one LF positive sample at week 28 (anti-LF antibody = 3.8 µg/mL).
Serum concentrations of anti-PA IgG and anti-LF IgG among responding subjects are shown in Figure 1. This figure illustrates the kinetics, magnitude and longevity of the anti-PA and anti-LF responses. The concentration ranges of anti-PA IgG and anti-LF IgG were 3.2–24.1 µg/ml and 1.9–37 µg/ml, respectively. The antibody responses for the majority of subjects peaked at Week 10, with a minority peaking at either Week 6 or Week 28. The duration of positive anti-PA and anti-LF antibody levels ranged from 10 weeks to 52 weeks with a median of 28 weeks. Because of the low frequency of seroconversion in the 0.2 mg and 0.6 mg dose level groups, it was not possible to define a relationship between vaccine dose level and magnitude of antibody concentration. All serum samples were also tested for TNA. TNA was positive in only 1 subject, who also was positive for anti-PA IgG (Fig. 2). At Week 28, the TNA ED50 titer was 32 and the corresponding anti-PA IgG was 15.9 µg/ml.
VCL-AB01 was well tolerated in monkeys. No deaths and no adverse clinical signs attributable to the vaccine were noted after 3 biweekly doses of the 0.6 mg dose level of VCL-AB01. In VCL-AB01 vaccinated monkeys, anti-PA and anti-LF antibodies increased over time (Fig. 2). By 8 weeks, anti-PA (10–22 µg/mL) and anti-LF (3–149 µg/mL) antibodies were present in all animals. At Week 10, immediately prior to challenge, values ranged from 21–58 µg/mL for anti-PA antibodies and 2–390 µg/mL for anti-LF antibodies. Similar to what was seen in the Phase 1 trial, TNA was not detectable in monkeys at 10 weeks, although one animal did show a positive TNA titer of 58 ED50 at Week 8 that became undetectable by Week 10.
At Week 10, animals received an average of 585 LD50 of Ames strain anthrax spores. Bacteremia was detected at Days 2, 4 and/or 6 in all animals in the PBS group and all but one animal in the VCL-AB01 group. Elevated body temperatures for 1–3 days (≥2°F above baseline) were observed in 3 of the 4 VCL-AB01 group while decreased body temperatures for 1–2 days (≤2°F below baseline) were observed in 2 of the 4 PBS group. No sign of illness including adverse clinical signs, bacteremia and temperature change appeared to correlate with mortality in individual animals (data not shown).
Despite the lack of TNA at Week 10, 3 of 4 (75%) animals survived challenge, with one VCL-AB01 vaccinated animal succumbing to challenge on Day 5, in contrast to 4 of 4 PBS-injected controls that died within 3–8 days. Anti-PA and anti-LF antibodies as well as TNA rose by several orders of magnitude by Week 13 (with, anti-PA antibodies ranging from 4,748–8,231 µg/mL, anti-LF antibodies ranging from 3,045–12,948 µg/mL, and TNA ranging from 11,296–23,676 ED50) indicating that a substantial, antigen-specific boost in antibody production occurred following spore challenge in each of those individuals. In addition to a lack of antibodies with detectable TNA prior to challenge, the animal that died had an anti-PA antibody concentration comparable to those of survivors, but had the lowest concentration (2 µg/mL) of anti-LF antibodies of the 4 vaccinated animals. Control animals (n = 4) demonstrated no antigen-specific antibodies or TNA prior to challenge and all died within 3–8 days after challenge.
During the past few years there has been substantial interest in developing pDNA-based vaccines for a number of infectious diseases. Potential advantages of pDNA-based vaccines include the speed, uniformity and cost of manufacture and the ability to elicit both humoral and cellular immune responses. These features, combined with the proven safety of administering nonadjuvanted pDNA doses as high as 8 mg, make this technology very attractive for an anthrax vaccine.
This was the first clinical trial to assess a DMRIE:DOPE formulation as an adjuvant for a prophylactic pDNA-based vaccine. Prior to evaluating VCL-AB01 in the clinic, the vaccine was tested in a repeated-dose toxicology study that included the 2 mg dose intended for use in the clinic, administered 4 times at 3 week intervals (an "n + 1" dosing regimen compared to that used in the Phase 1 clinical trial). Each dose administered in the rabbit study was approximately 28 times the single human dose on a mg/kg basis, assuming a 2.5 kg rabbit and a 70 kg human, thereby providing an adequate safety margin for translational assessment of the vaccine. The results from this study demonstrate the safety of the vaccine in rabbits, with no evidence of an adverse systemic response or injection-site reactogenicity. In monkeys, although no formal toxicity profile was determined, 3 vaccinations with the 0.6 mg dose of VCL-AB01 induced no local or systemic signs of adverse reactions to the vaccine.
The results from the rabbit toxicology study, in addition to studies demonstrating immunogenicity and efficacy, adequate clearance of the pDNA over time (data not shown), and the lack of potential for integration of the pDNA into the host genome,15 were used to support clinical testing of the vaccine. The primary endpoints of the Phase 1 trial were the clinical and laboratory safety and tolerability profiles. The rabbit toxicology data were, in general, predictive for the majority of the same parameters investigated, with no observed changes in biochemistry or hematology parameters noted after injections. The exception appears to be injection site pain, which is difficult to measure in rabbits and requires a severity that results in favoring of the injected limb. In contrast to the results seen in rabbits with the 2 mg dose, dose-related reactogenicity and some systemic responses to VCL-AB01 were observed in humans at that dose, although the changes in clinical signs observed (fever, headache and injection-site pain) are not atypical for vaccines and were transient, resolving within days for all subjects. Injection site pain in humans appeared to be dose-dependent. All subjects who received the first injection of the 2 mg dose reported grade 3 injection site pain and two out of ten subjects reported systemic symptoms. Based on the local and systemic reactions to the 2 mg dose, the high dose group did not receive the full dose vaccine series and instead was boosted with the next lower tolerated dose, 0.6 mg, at 6 weeks after the first injection, with one more dose administered approximately 5–6 weeks after the second dose. Reduction of the dose to 0.6 mg resulted in fewer AEs for that group after both the second and third injections. The 0.2 and 0.6 mg doses of the vaccine were well tolerated in human subjects. In monkeys, the 0.6 mg dose also appeared to be well tolerated.
Previous studies have measured anti-PA antibody levels in volunteers receiving licensed AVA or investigational rPA vaccines, 6,7,16 as well as in individuals infected by anthrax spores through cutaneous or inhalational routes.17 TNA has been shown to correlate with the level of anti-PA antibodies produced in response to protein-based vaccines,17 and has been shown to correlate with antigen-specific antibodies in monkeys that survive lethal B. anthracis challenge. Therefore, for protein-based vaccines, TNA or anti-PA antibodies have been selected as an appropriate correlate of protection expected to be raised against an anthrax vaccine in humans. The anti-PA antibody seroconversion frequency (40%) and the amount of PA-specific antibodies in subjects receiving the highest dose of VCL-AB01 (3.2–24.1 µg/ml) were lower than in subjects receiving AVA in a previous study (100% seroconversion frequency and a range of 15–147 µg/ml). More importantly, TNA was not detected in the majority of subjects who seroconverted, irrespective of dose level or numbers of doses administered, but LF-specific antibodies were detected in 50% of subjects (1.9 µg/ mL–34.9 µg/mL). Unfortunately, it is unknown whether higher PA- and/or LF-specific antibody concentrations, and even TNA, could have been elicited in the Phase 1 trial had the intended 2 mg boosting doses been administered to the 2 mg group instead of the 0.6 mg doses.
Since a correlation has been established between anti-PA IgG and TNA (r2 = 0.83),17 and only a minority of subjects had measurable anti-PA IgG levels, the finding that TNA was not detectable in most subjects is not surprising. However, it is important to note that there was a significant increase in the number of seroconverters to either PA or LF when comparing the high and the low dose groups (Table 3), and more importantly the monkeys that received 3 × 0.6 mg doses of the VCL-AB01 vaccine survived the challenge despite the lack of detectable TNA prior to challenge and low anti-PA and anti-LF antibody concentrations measured using the same assay methods used for evaluation of the human sera. Low to undetectable levels of antibodies determined by ELISA and TNA assays, respectively, did not predict protection in monkeys. Despite the absence of detectible TNA and in the presence of low concentrations of anti-PA and anti-LF antibodies, 75% of VCL-AB01-vaccinated monkeys survived a B. anthracis lethal challenge that killed all PBS injected controls within 3–8 days. These results suggest that for this pDNA-based vaccine, anti-PA IgG levels and/or TNA levels alone did not sufficiently predict protection against inhalational anthrax in primates. Therefore, based on results from these assays, it is not known if humans vaccinated with VCL-AB01 would have likewise been protected with this pDNA-based vaccine against exposure to anthrax spores. Interestingly, the high serological responses in monkeys following spore challenge is suggestive of an anamnestic response that may represent adequate priming of the immune response to sufficiently protect vaccinees despite the lack of obvious serological indicators. Bacteremia was detected in 3 of 4 VCL-AB01-vaccinated animals at 2 and 4 days after challenge that may have provided antigen for boosting the low level immune responses, although one survivor in this group had no detectable bacteremia (data not shown). Further studies are necessary to understand the breadth of immunological responses to this and perhaps other pDNA-based vaccines.
Collectively, these results suggest that VCL-AB01 vaccine is safe and well tolerated at the 0.6 mg dose, both in humans and monkeys. They also suggest that TNA titer, an adequate predictor of protection of protein-based anthrax vaccines, may not be the optimal predictor of protection for this pDNA-based anthrax vaccine. In addition, high concentrations of anti-PA antibodies may not be required for protection following immunization with this pDNA-based vaccine. These results imply that vaccination with this pDNA-based anthrax vaccine may elicit a potent memory response that can be boosted extremely rapidly following exposure to anthrax spores and indicates that an alternative correlate of protection besides serum antibody levels should be explored for this and perhaps other pDNA vaccines. Recent evidence with a pDNA vaccine intended to prevent cytomegalo-virus reactivation in hematopoietic stem cell transplant recipients suggests that a cultured interferon-γ enzyme-linked immunosorbent spot (ELISPOT) assay detected priming of antigen-specific memory T cells in subjects who failed to demonstrate responses by an ex vivo ELISPOT assay. These data suggest that assays such as the ex vivo ELISPOT assay that measure only effector responses may not suffice for detecting immunological priming by pDNA-based vaccines. Further studies of VCL-AB01 in monkeys are warranted to determine if a similar cultured antigen-specific B cell ELISPOT assay will provide evidence of memory that is predictive of protection.
The VCL-AB01 vaccine is composed of two covalently closed circular plasmids, VCL-6292 and VCL-62952 combined in equal mass amounts and formulated with a cationic lipid delivery system described below. These plasmids have been described previously.11 VCL-6292 contains a human codon-optimized gene encoding a detoxified B. anthracis PA. To prevent the expressed PA protein from processing into a mature, biologically active protein, the furin cleavage site (RKKR) was deleted from the PA coding sequence. Therefore, the expressed PA antigen, (PAΔfurin) is not active even in the presence of wild type LF.11
VCL-62952 contains a human codon-optimized gene encoding a detoxified B. anthracis LF that is truncated at amino acid 583 to remove the entire domain IV containing the metalloprotease enzymatic activity. The expressed antigen, referred to as LF [I–III], has been shown to be nontoxic even in the presence of wild type PA,11
VCL-AB01 plasmids are formulated with the cationic lipid delivery system, DMRIE/DOPE. DMRIE, synthesized as DMRIE-Br (CAS name: (+)-N-(2-hydroxyethyl)-N, N-dimethyl-2,3-bis(tetradecyloxy)-l-propanaminium bromide) is a cationic lipid with a molecular weight of 636.89 (Fig. 1). DOPE (CAS name; l,2-dioleoyl-sn-glycero-3-phosphoethanolamine) is a zwitterionic phospholipid with a molecular weight of 744.04. These two lipids are formulated at a 1:1 molar ratio and complexed with plasmid at a 4:1 molar ratio of DNA:cationic lipid.
The purpose of this study was to evaluate the safety of VCL-AB01 following repeated intramuscular (IM) administration in New Zealand White rabbits on Days 0,14,28 and 56. This study was performed in accordance with Institutional Animal Care and Use Committee (IACUC)-approved protocols, with the Guide for the Care and Use of Laboratory Animals (National Academy Press, 1996), and in compliance with the Good Laboratory Practices as set forth in 21 CFR 58.
Eighty New Zealand White rabbits (40 males and 40 females) approximately 13–17 weeks old with body weights between 2.2 and 2.9 kg at the onset of the study were used. Four groups of ten animals per sex were used in each test group. Each animal was injected IM in the vastus lateralis (the same muscle for each administration) with 1 mL of either PBS, a. low (0.2 mg/mL) or high dose (2 mg/mL) concentration of VCL-AB01 [1 mg each of VCL-6292 and VCL-62952 plasmids formulated with DMRIE/DOPE (964 µg DMRIE/1,128 µg DOPE) in PBS]. The 2 mg/mL dose was the highest dose of VCL-AB01 used in the Phase 1 clinical trial. A high dose (2 mg/mL) VCL-AB01 pDNA in PBS was used as a control to evaluate any possible safety issues associated with the DMRIE/DOPE delivery system. All test and control articles in this study were produced and packaged in Vical's manufacturing facility according to current Good Manufacturing Practices.
Animals were evaluated daily throughout the study for adverse clinical signs (ill health and behavioral changes). Injection sites were scored for signs of edema and erythema once during the pretreatment period, and daily throughout the study, and were graded on a scale of 0–4 for severity (Draize scoring), Fundoscopic (indirect ophthalmoscopy) and biomicroscopic (slit lamp) examinations were performed by a board-certified veterinary ophthalmologist on all animals once during the pretreatment period and once within 48 hours prior to sacrifice. Food consumption and change in body weights were monitored throughout the study. Laboratory investigations (hematology, coagulation and clinical chemistry) were performed on sera taken from all study animals once during the last week of the pretreatment period, and once each during Weeks 2, 4, 6, 8, 10 and 12. Sera taken from each animal were also evaluated for anti-nuclear antibodies and antibodies to ds DNA.
Five animals/sex/group were sacrificed 48 hours following the last injection. The remaining animals (5 animals/sex/group) were sacrificed four weeks following the last injection. Full necropsy was performed on all animals at both time points for gross and histological evaluation to determine if there were any pathological changes associated with 4 repeated injections of VCL-AB01 at either the high or the low dose compared to controls.
Numerical data were subjected to calculation of group means and standard deviations. Data were analyzed using the analysis of variance (ANOVA) and the significance of inter-group differences was analyzed using Dunnett's t test. Statistical analysis was performed using SPSS for Windows, Version 11.0.1 (SPSS, Inc., Chicago, IL).
A Phase 1, randomized, double-blind, placebo-controlled, dose-escalating trial of VCL-AB01 was conducted at two sites, Baylor College of Medicine (Houston, TX) and the University of Rochester (Rochester, NY) from the summer of 2004 to the fall of 2005. The trial was performed to evaluate safety and immunogenicity according to a protocol approved by each center's respective Institutional Review Board and Institutional Biosafety Committee, and was conducted in accordance with Good Clinical Practice (GCP) and the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules Section III regarding human gene transfer experiments.
Healthy nonpregnant adults between the ages of 18 and 45 years were recruited to participate. Eligible subjects did not have acute or chronic illnesses by history or laboratory screening, and reported no history of allergy to vaccine components or history of severe reactions to vaccines. Receipt of anthrax vaccine in the past was an exclusion criterion. After giving informed consent, eligible subjects were randomized through a web-based data acquisition system (EMMES Corporation, Rockville, MD) to one of 4 study groups to receive investigational vaccine at a dose of 0.2 mg, 0.6 mg or 2 mg of total pDNA or PBS placebo administered at 0, 1 and 2 months (Table 1). Groups were enrolled sequentially at higher doses with a 14 day pause between groups for safety evaluation. Vaccine or placebo was administered as a 1 mL IM injection into the deltoid muscle of alternating arms for each injection. Subjects kept a daily diary of injection site and systemic symptoms and oral temperature during the week following each vaccination. Solicited local and systemic symptoms including discomfort, temperature, fatigue, chills/feverishness, rash and loss of appetite were evaluated. Concomitant medications taken during the trial were documented. Subjects were monitored after each immunization and examined on Days 2, 7 and 14 after each immunization for potential clinical AEs. A final phone call was made approximately 12 months after enrollment to identify and document the occurrence of any intercurrent SAE. A Safety Monitoring Committee consisting of one independent safety monitor at each site and at least one other independent safety monitor evaluated the safety results prior to dose escalation. Due to injection site reactogenicity observed at the 2 mg dose level after the first immunization, the second and third immunizations in that Group were de-escalated to 0.6 mg. The schedule for the 0.6 mg group was delayed up to 2 weeks to complete the evaluation of the dose-related toxicity.
Blood samples for safety assessments were taken at Day 7 after each immunization. Biochemical and hematological evaluations performed included the following: human chorionic gonadotropin (when appropriate), blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, anti-double stranded DNA antibodies, ANA, hematocrit, hemoglobin, white blood cell count, platelet count, neurrophil count, lymphocyte count, eosinophil count. Antibody assays were performed using sera collected on Days 0, 14 and 28 and Weeks 6, 10, 28, 39 and 52. Sera were analyzed for anti-PA and anti-LF antibodies by enzyme-linked immunosorbent assay (ELISA) and for antibodies with toxin neutralizing activity (TNA) by an in vitro cell-based assay developed at the U.S. Centers for Disease Control and Prevention (CDC),18
The primary reactogenicity endpoints were the frequency and severity of solicited local and systemic AEs. Symptoms were graded as absent, mild (grade 1; noticeable but with no activity impairment), moderate (grade 2; sufficient to interfere with usual activities), severe (grade 3; incapacitating or unable to perform usual activities), or life-threatening (grade 4). Grade 3 and 4 reactions were considered to be SAEs. Injection site redness and swelling were graded based on size (0 = <5 mm; 1 = 5–49 mm; 2 = 50–99 mm; 3 = ≥100 mm). Fever was defined as an oral temperature ≥100°F.
The immunogenicity endpoints were the seroconversion frequency and levels of serum antibodies against PA and LF after receipt of all 3 doses. Clinical and serologic responses (PA- and LF-specific antibodies measured using ELISA and TNA) were assessed before and after each immunization, as described.
Differences in dichotomous variables were compared by chi-square or Fisher's exact tests and continuous variables were compared using paired t tests and ANOVA. Linear least squares regression analyses of titers after immunization were used to evaluate dose response relationships, controlling for preimmunization antibody titers and gender. Statistical analyses were performed using SPSS version 14.0.2 (SPSS, Inc., Chicago, IL). The sample size determination was based on empirical evidence gathered from prior Phase 1 trials, in which the number of subjects per dose was adequate to rule out common AEs. If 10 subjects per dose group are enrolled, there is a 95% confidence of observing at least one occurrence of a specific AE given that the true proportion that would develop this AE in the population is 30%.
The ELISA to quantify anti-PA IgG in human and monkey sera was performed at Vical Incorporated according to the method of Quinn et al.18 with recombinant PA (List Biological Laboratories; Campbell, CA) as a solid phase immobilized antigen and horseradish peroxidase (HRP)-conjugated mouse anti-human gamma chain-specific (PAN) monoclonal antibody (clone HP6043, Hybridoma Reagent Laboratory, Baltimore, MD) with 2,2'-azino-bis-(3-ethylbenzylthiazoline-6-sulphonic acid, ABTS) substrate (Kirkegaard & Perry Laboratories, KPL, Gaithersburg, MD) as the reporter or signal system. For monkey sera, HRP-conjugated mouse anti-monkey IgG was used instead of mouse anti-human IgG. Each plate was required to pass acceptance criteria using CDC reference serum. Subjects were considered to be responders to PA if one or more of their serum samples collected after vaccination: (a) exceeded the reactivity threshold of ≥3 µg/mL18 for a subject with nonreactive or 0 values before vaccination, or (b) increased by ≥4 fold relative to baseline values for subjects with ≥3 µg/mL of PA antibody before vaccination.
The ELISA to quantify anti-LF IgG in human and monkey sera was performed at Vical Incorporated according to the method of Selinsky et al.19 This method is similar to that of the PA ELISA with the following modifications: (1) wells of Immulon 2-HB 96-well plates were coated with recombinant LF protein (List Biological Laboratories; Campbell, CA) in PBS; (2) the positive control, VCT530, was serially diluted two-fold in ELISA diluent [PBS containing 5% skim milk and 0.1% polyoxyethylene sorbitol monolaurate (Tween 20)] starting at 1/100 and, (3) each dilution was assayed in duplicate. For monkey sera, HRP-conjugated mouse anti-monkey IgG was used instead of mouse anti-human IgG. Each plate was required to pass acceptance criteria based on the performance of standard reference and quality control sera assayed in parallel with the test sera. Subjects were considered to be responders to LF if one or more of their serum samples collected after vaccination: (a) exceeded the reactivity threshold of ≥1.75 µg/mL19 for a subject with nonreactive or 0 values before vaccination, or (b) increased by ≥4 fold relative to baseline values for subjects with ≥1.75 µg/mL of LF antibody before vaccination.
The ability of human and monkey serum samples to neutralize the cytotoxic effects of anthrax lethal toxin was measured using the J774A.1 mouse macrophage cytotoxicity assay as previously described.17 TNA assays were performed at Vical Incorporated using a protocol and serum standards provided by Conrad Quinn, CDC. The reciprocal dilution of serum antibody that resulted in 50% neutralization of lethal toxin-mediated cell death (the ED50) was determined using a 4-PL curve fitting algorithm performed by SAS software (version 8.0) running an end-point calculation algorithm developed by the CDC.l8 Data were reported as the ED50 titers. To be considered a positive result, at least 2 points were required to be present on the curve above the threshold titer (TT) and the TT had to be at least 2x the starting dilution.
VCL-AB01 was evaluated in a B. anthracis lethal spore challenge model at the Battelle Memorial Institute (Columbus OH). This study was performed in accordance with Batelle's Institutional Animal Care and Use Committee approved protocols, and with the Guide for the Care and Use of Laboratory Animals (National Academy Press, 1996).
Only healthy animals prescreened to confirm seronegative status for anti-PA and anti-LF antibodies were included. VCL-AB01 from the same lot used in the clinical trial was administered as 0.6 mg/1 mL IM injections to cynomolgus macaques (2/sex) on Days 0, 14 and 28. A second group of controls received 1 mL IM injections of PBS according to the same schedule. All animals were aerosol challenged using a head-only exposure system 6 weeks after the last vaccination with an average dose of approximately 585 LD-50 Ames strain spores (range 311–1341). Spores were produced in a New Brunswick BioFlo 4500 Fermentor/Bioreactor (Edison, New Jersey) from a well characterized parent stock. A scale-up inoculum was produced and used to initiate fermentation, which continued until approximately 95 percent sporulation was reached. The culture was heat shocked for 45 min at 60°C, harvested, washed with sterile water and suspended in sterile water with 1% phenol for storage at 2–8°C. This spore lot was characterized for consistency with parent stock and purified by density gradient centrifugation. After challenge, animals were monitored closely for signs of disease. Temperature and bacteremia were also monitored (daily for 2 weeks and on Days 2, 4 and 6, respectively). Moribund animals were euthanized. Antibody assays to detect anti-PA and anti-LF antibodies and TNA were performed from sera collected prior to vaccination and at Weeks 4, 8, 10 and 13 (3 weeks after challenge).
The authors would like to thank Lisreina Toro, Robert Atmar, Shital Patel, Janer Wells and the staff at Baylor College of Medicine; Carrie Nolan, Diane O'Brien and the staff at the University of Rochester, School of Medicine and Dentistry; Holli Hamilton, Steve Heyse, Rosemary McCown, Ed Nuzum, Janet Shimko and Lanling Zou at the NIH/NIAID/DMID for their assistance with the clinical trial; Mark Perry, Jim Long and the staff at The Battelle Memorial Institute, Alice Chu for statistical analyses; and Dr. Holly Horton, Gail Fieser and Jackie Stupack for their expertise. We gratefully acknowledge the Safety Monitoring Committee members (Robert Edelman, Ann Falsey, Richard Sutton) for their participation in the clinical trial.
The nonclinical studies were supported by SBIR grant # 2R44AI053060-03. The clinical trial was supported by contracts N01-AI-25465, N01-AI-25460 and M01 RR00044 (NCRR).
Presented in part at the 2005 Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA.
Financial disclosure
A.R. and L.R.S. are employees of Vical Incorporated and declare financial holdings in the company.
PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's national science library in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers.


text:
Easy French in 10 days # day 1
Online Education, Instructor
- 0.5x
- 1x (Normal)
- 1.25x
- 1.5x
- 2x
LE VERBE Être et avoir - VERB to be and to have3:27
Prépositions devant les villes/pays - Prepositions before cities/countries3:34
Les questions en Français - French questions2:34
Conjugaison des verbes en ER - conjugating french verbs ending in er3:17
Le verbe (Aller) - the verb (to go) - Examples3:47
Les articles - le, la, l', les - un, une, des - (The) (a) and (some) in French4:39
Apprendre mon, ton, son - notre, votre, leur - Les adjectifs possessifs4:23
La negation en Francais - make negative sentence in French3:07
Apprendre plus des verbes en ER - List of Regular ER French Verbs conjugated4:02
Une liste des prépositions pour vous faciliter- link the words with prepositions4:15
Les adjectifs sont très imp - adjectives are very important, let's learn some3:44
Les couleurs vous aide à faire le bon choix - learn colors and make choice3:23
Les jours/mois/saisons - days/months and seasons in French with Ex..3:44
Mots français les plus courants - Some useful french words & phrases4:29
Les adjectifs demonstratifs - CE, CET, CETTE AND CES demonstrative adjectives4:27
Pouvez-vous épeler votre nom ? French alphabet/ How to spell a word in French2:22
Apprendre les animaux en Francais - Learn the Animals1:43
Apprendre les fruits en Francais - Learn fruits in French2:24
About This Class
What are the requirements?
- A pen and a paper could be useful to take notes
What am I going to get from this course?
- Over 20 lectures and 1 hour of content!
- learn to ask and make different questions
- learn verbs - sterms and endings
- learn pronouns & adjectives
- Language learning strategies
- Negation
- Gender and number of nouns
- Descriptive adjectives and agreement
- etc.
What is the target audience?
- Everyone is free to take this course
Class Projects 1 See All
Bonjour ! , my name is Ylber, I was born in Novosello, a small village in the south east of Kosovo, now I live in Montpellier which is a city in south of France, exciting and much more dynamic. I studied French Literature at the university of Montpellier but also English as a foreign language. I have been teaching for 5 years now in many schools and associations. I really enjoy teaching. It gives me the opportunity to learn about the different cultures around the world.
I have become a self taught, Depending on the complexity of a topic, learning something new can take a long time. And it's bound to be frustrating as you grapple with new terminologies, new models, and apparently irrelevant information. When you are learning something by yourself, there is nobody to control the flow of information, to make sure you move from basic knowledge to intermediate and finally advanced concepts.
Keep in mind these three things :
1. Believe in God
2. be patient and
3. never give up !
Patience with your topic, and more importantly with yourself is crucial — there's no field of knowledge that someone in the world hasn't managed to learn, starting from exactly where you are.
I'm constantly trying to improve my teaching skills in order to satisfy the needs of my students. Internet is a very useful tool to experience new methods
I truly believe that learning new things opens the mind and allows you to be more tolerant. I'm quite open minded and flexible and always promote a positive way of learning - I like to tailor my lessons to my students' needs so that I really can help them progress at their own place in a fun and caring environment!
My job is a passion and I look forward to share my expertise with you ! A bientôt !
I hope you enjoy learning as much as I enjoy teaching !


text:
Shanna WarnerGreensboro, North Carolina, US
I have a rather low voice for a woman with no high pitches or tones. I can drop it further for an almost sultry, mysterious tone suitable for a wide variety of advertisements. I am an excellent choice for movie trailers, commercials, narration, or documentaries. I can also adapt a very serious and professional tone that would be appropriate for business applications. Irish/Celtic accents come very easily to me as do British accents.
English (North American), English
British, Celtic, North American
Young Adult
Special Skills
Audiobooks, Business, Cartoons, Documentaries, Educational, Internet, Movie Trailers, Podcasting, Radio, Telephone, Television, Videogames
I have been an avid reader since the age of 4 and I have a college education.
Samson C01
Computer & Software
Custom built Intel 2011 desktop with high end content creation hardware and software including Adobe Audition
Special Equipment
Six-core system equipped with a Creative Zx sound card and multiple audio engineering programs
Delivery Methods
Email, cloud, USPS, and/or courier (UPS, FedEx)
Turnaround Time
I will be happy to provide an accurate quote when contacted with project opportunities. The turnaround time will be dependent on the scale of the project (movie trailer versus audio book).
Service Description
I am a perfectionist who strives to put maximum effort into every aspect of my life. I will make your project a success by giving you 110%. I would like to get as clear of an idea as possible regarding your expectations and deliver those expectations. My goal is to give you what you are looking for in one attempt.
Payment Terms
Hire Shanna as a voice actor. Payment is made through Voices.com SurePay, an escrow service that guarantees your work is done to your satisfaction. Send payment securely by Visa, Mastercard or PayPal through Voices.com then download your files from the website.
Watch a video to see how to make a payment
Next Steps
To contact Shanna Warner about your project, request a quote today. We'll walk you through the process step-by-step. It's fast and easy.
Hire Shanna Warner as a voice actor. Working with Shanna Warner is fast and easy. We'll walk you through the process step-by-step.
Request a quote for your project today.


text:
Endangered Wolf Society Polo Match
Endangered Wolf Society Polo Match Endangered Wolf Center By Diane Anderson Endangered Wolf Center held their biggest fundraising event of the year. The St. Louis Polo Club treated guests to a charity polo match. This casual event offered those who attended a rare chance to see this thrilling, fast-paced sport in action. There was also on display and antique car show, kids' activities and the Anheuser-Busch Clydesdales. The purpose of the Endangered Wolf Center is to save wolves and other wild canids from the precarious path toward extinction. Spotted in the crowd were Ralph Pfremmer, chairman of the board, and Ginny Busch, executive director.
Subscribe to the Early E-Edition
Be the first to receive Ladue News in your inbox before it hits the newsstands.
Aug 27Villa Antonio Winery
Feb 11
Nov 30Sheraton Westport Chalet Hotel
Aug 18Villa Antonio Winery
Aug 19Tigin Irish Pub in the Hampton Inn


text:
It only takes a minute to get started. Fill out our uncomplicated sign up form and login to the website.
This step is voluntary but will greatly multiply your chances of having members look at your profile. Write a few sentences about yourself, your interests and upload any nice photographs of yourself.
Use our website's state-of-the-art search to find members who satisfy your needs. Or just look through listings and find folks that appear interesting.
Discovered someone who could be interesting? Send them a few words or just a wink and see if they're interested. With a little luck you'll be on your way to true love.
And start dating


text:
No More Mucus
by Dr. Melody Shubert, D.C. on July 8th, 2014
I first heard of the new allergy treatment at a fair. Thought it wouldn't work, but then i thought "no needles" maybe I will give it a chance. Got tested and then on my first treatment for "mucin", I felt the effects almost immediately. My throat has been clear of mucus since. I have not coughed or had the feeling of an itching throat.
Disclaimer: results will vary from person to person
Disclaimer: results will vary from person to person
Posted in Success Stories Tagged with no tags
0 Comments
Leave a Comment
Submit Your Own Testimonial
Write a Review for Advanced Allergy Relief of KansasWrite a Review on Google
Recent Success Stories
Success Stories (10)


text:
As companies grow, it's imperative for their corporate images to evolve as well. One component of that change includes corporate identity. Embarking on a journey to change existing marketing materials is more of a challenge than some anticipate. Read about one company's experience with updating their logo.
By Christina Soave
Public Relations, Product & Marketing Coordinator for Boston International, Inc.
No doubt it's a scary leap to rebrand an established business- will people still recognize us? Will our consumers and employees like this change? How can this be done without harming the equity of the company? Will the ever-growing to-do-list of re-branding be too overwhelming?
Many of these questions were on the minds of Boston International employees when our company, a leader in gift housewares decided to re-brand the company and unveil a new logo this year. This would mark the most dramatic change in the company's visual identity since its inception in 1986. The decision to make this change was made when we felt like our current logo wasn't communicating our new "modern" and "evolving" direction.
Our first step was to reach out to a professional with marketing communications experience. That's where Peter Harris Creative out of Keene, New Hampshire dove in to get us started. The entire process took about 6-8 weeks starting with an initial survey distributed to BI's key players. The survey was for Peter Harris Creative to get a feel for our primary customers and their relationship with us, our critique on the current logo, desires for the new one and essentially what was working for us and what was not.
The critique of the previous logo concluded that our company name does not say a lot about our company or its products. It was also cumbersome, coming in at a whopping 7 syllables, therefore the new direction would focus on the initials "BI", our nickname. It should also capture our company's contemporary and energetic spirit.
The toughest part came with the design process, sorting through the varying ideas and opinions regarding the new logo concepts at hand. To get management and staff on the same page seemed to be a struggle. Choosing colors was another challenging task and involved lots of research about what different colors mean and what these colors say about you as a company. This led us to blue, a calming color, and orange, reflecting excitement and enthusiasm to make a balance. Lastly, we had to make sure the logo would work well graphically with our products, catalog and brand as a whole.
We learned that branding is reciprocal and feedback will vary. Once the initial logo was definite and its meaning clear, we were ready to share it and its meaning to our audience. The new logo accentuates our initials "BI" and captures the artistic nature of the company through an exclusive hand-drawn font and watercolor effect. We are excited to be unveiling our new logo at the Atlanta International Gift and Home Furnishing Market this July 2015. To share in our enthusiasm, we will be holding a launch party on Friday night during the show and giving away fashion totes sporting the new logo. We feel it's a symbol of the many exciting developments to come for "BI", and we hope to share our passion for the gift industry. The details for the party and other show specials can be found below.
Boston International Logo Launch Party
Boston International Showroom #819
AmericasMart- Building 2, 8th floor
Friday July 10th– 6pm-8pm
BI Show Specials:
Orders $300-$799 with immediate shipping receive a 5% freight cap
Orders $800 and more with immediate shipping receive Net60 and a 5% freight cap


text:
View map Map
There are no results which match your criteria. Try refining your search parameters.
There are a lot of places to rent for a summer vacation on the Lower Cape. There are only a few Pretty Picky Properties. Most are directly on or very near the beach. Our homeowners love their properties, fastidiously maintain them, and expect guests to treat them accordingly. Our guests demand a prime location and a vacation experience that far exceeds the typical Cape summer rental. When you spend a good amount of money for a perfect summer vacation, you want to be sure before you commit. That's why we take the time to carefully and completely answer all your questions by phone or email. If you can visit the Cape in advance, we'll be happy to show you one or more properties you're considering. Most guests are also comforted to know that Pretty Picky also has a property management division, Monomoy Property Services. Most unforeseen property issues can be resolved quickly with our ready access to maintenance resources. We look forward to helping you plan your ideal Cape Cod vacation!
Our mission is to provide discriminating vacationers, typically families with children, with the best Cape Cod vacation experience ever!
Besides the usual rental broker services, we offer a value added rental service experience. For example, in most cases, we personally meet and greet arriving rental guests at the property, taking the time to provide a brief orientation and review any unusual property features and beach access, as well as owner-approved guidelines. We also answer any guest questions and make suggestions resulting in a more enjoyable stay.


text:
Men's Sports
Women's Sports
Men's Sports
Women's Sports
| TheW.tv | WCC on Instagram | WCC on Facebook
SAN BRUNO, Calif. – The West Coast Conference has named its Men's Basketball Player of the Week for February 15, 2016.
Freshman guard Nick Emery led BYU to a pair of road wins at San Francisco (114-89) and Santa Clara (96-62), averaging 34.0 points, 2.0 rebounds and 3.0 assists while shooting 69.4 percent from the field, 65.0 percent from 3 and 100.0 percent from the free throw line.
Against San Francisco, Emery scored a BYU freshman record 37 points and tied the team record with 10 3-pointers. He got the Cougars out to a 58-39 lead at the half with 20 points in the first half. He hit 5 of 6 from 3 in the first half and did the same in the second. He finished the game shooting 12 of 15 from the field and 10 of 12 from 3-point range. His 37 points are the second most scored by an individual in WCC play this season.
At Santa Clara, Emery scored 31 points to become the only Cougar to score 30-plus points in back-to-back games as a freshman. Emery led BYU to a 51-32 lead at the half with 18 points on 7 of 10 shooting.
For the weekend, Emery connected on 25 field goals, 13 from long distance. His 10 triples against the Dons were the second most in WCC history behind LMU legend Jeff Fryer, who connected on 11 in an NCAA Tournament win against Michigan (3/18/90).
Also Nominated: Amadi Udenyi, Pepperdine
2015-16 WCC Men's Basketball Player of the Week
2/15 – Nick Emery, BYU
2/8 – Alec Wintering, Portland
2/1 – Kyle Wiltjer, Gonzaga
1/25 – Adom Jacko, Loyola Marymount
1/18 – Jock Landale, Saint Mary's
1/11 – Kyle Collinsworth, BYU
1/4 – Jared Brownridge, Santa Clara
12/28 – Alec Wintering, Portland
12/21 – Domantas Sabonis, Gonzaga
12/14 – Stacy Davis, Pepperdine
12/7 – Nate Kratch, Santa Clara
11/30 – Kyle Collinsworth, BYU & Kyle Wiltjer, Gonzaga
11/23 – Domantas Sabonis, Gonzaga
11/16 – Kyle Davis, BYU
© Copyright 2017 West Coast Conference. All Rights Reserved.


text:
Welcome Log in Your account
|Welcome to Kitten's Playpen!
You must be 18 years of age to purchase Novelty items. These items are located in the Novelty section. You must LOG IN to see this section of the shop.
You agree to read our FAQ prior to ordering. All Processing/Shipping times are located there,and we all want you to be as informed as possible! :)
If you have any questions about our products,the FAQ,or anything else please contact us <3
Thank you for your understanding!
No products
$0.00 Total
-All items sold here are in USD.
-We accept international orders.
-Our checkout process uses PayPal (PayPal.com)
If you receive a "Payment Error"
Most payment errors happen when the billing address doesn't match the address connected to your credit card. Make sure that the billing address matches the address on your credit card. If you are using a prepaid credit card (such as Vanilla Mastercard or Visa prepaid) make sure that you have registered your card at www.vanillamastercard.com or at www.visa.com.
We have found that this is the most common error. If this doesn't resolve the issue let us know and we can invoice you for your order directly through Paypal.
Is your packaging discrete?
-Our packaging is discreet, however we do attach cute stickers to the outside of the package.
-The package arrives with the company name " KPP Inc.".
-We do not put anything on the label that indicates what's inside.
-Please make a note on your order if you'd prefer no stickers on the package.
How long will it take for my in stock items to ship?
-During busy periods (i.e. holidays, convention season, etc.) we experience larger volumes of orders. Processing times could increase by approximately 4-6 weeks. We are currently in a busy period and experiencing delays, so please keep that in mind when ordering.
-If you order in December, you will most likely not receive it in time for Christmas taking into account the processing time and delivery/shipping times. Please take into consideration the total time it takes to arrive to you before ordering a gift. We suggest ordering a gift card instead if ordering a gift in December.
-Processing times when we are not in our busy holiday period is approximately 10 business days. This does NOT include delivery time.
-Please allow for postal delivery times based on your postal carrier and method of shipping chosen.
- If you need your order for a specific date,please contact us via email and will try our best to accommodate. We recommend paying for a faster shipping to ensure your order arrives before this date.
- Orders can be delayed if products required to complete the order are not currently in stock or back ordered through a supplier . We will contact you if this occurs before the estimated processing window to ensure your order goes out quickly.
How do I find out my order status & tracking info?
- You can check your order status on our site! Simply log onto your account, and go to your account's order history.
- You will only see the tracking number for your package if you chose tracked shipping method at checkout.
- The tracking number will be available only after the order is shipped out.
What are the delivery estimates once shipped?
North America
Standard (no insurance,no tracking number) - Approximately 8 to 20 business days to arrive after being shipped
Tracked (comes with insurance and tracking number) - Approximately 7 business days
Standard Surface (no insurance,no tracking number) - Approximately 6 to 14 weeks.
Standard Air (no insurance,no tracking number) - Approximately 3 to 12 weeks.
Tracked International (comes with insurance and tracking number) - Approximately 7 to 11 business days
What If My Package Is Lost?
-If you selected a shipping method with a tracking number, we can file a claim with CanadaPost, and have replacement items sent to you as soon as possible :)
-We are NOT liable for any packages sent "Standard". There will be NO compensation for any packages lost that are sent with "Standard" because we are unable to file a claim without a tracking number. Because of this we strongly suggest to pick a method with a tracking number. It is worth the price difference.
Can I combine my orders?
What about Made to Order/Custom/Build Your Own items? (NO LONGER AVAILABLE TILL FURTHER NOTICE)
-Custom orders have been closed and will remain closed until we get through all of our remaining custom orders.
- We cannot guarantee a certain processing time for custom orders,due to the large number of changes we have been receiving with the orders that we received. We also do not want to rush the orders and negatively impact the quality of our products. There is no way to accurately estimate the processing time due to these variables. You can ask us at any point about the status of your order by emailing us.
- Orders can be delayed if materials or products required to complete the order are not currently in stock or back ordered through a supplier. We will contact you if this occurs.
-Your order will be delayed if you make alterations to your order.
- Your order will be delayed if you do not reply to our order confirmation emails when working on your custom
order. It is imperative that you get back to these emails as not responding may result in your order not being shipped.
- Every custom order is organized into a specific group:
Tail Order - The order only consists of tails
Ear Order - The order only consists of ears
Collar Order - The order only consists of collars
Group Order - The order consists of a variety of different items
We have a staff of 5, and certain people specialize in making a specific item. Because of this, a certain type of order (Example: Collar Order) may be ahead more than another type of order.
If you have any questions or concerns regarding shipping times and processing times on custom orders please email us at email@example.com and we will respond between Monday-Friday.
- If you have a problem with an order from our store or would like to cancel an order, please contact us at firstname.lastname@example.com.
-Please provide your order reference code in the body of your email, the reason for the refund or exchange.
Can I cancel my order?
-When cancelling custom orders that have already been started, refunds will be handled on a case by case basis based off of the time and materials already invested into the order.
- When cancelling in stock items within the expressed processing time of up to 4 weeks,there will be a restocking fee of 10% of your order,excluding shipping.
-For instance if an ear and tail set was ordered and the ears were already completed to your specifications, we will refund the tail and a percentage of the ears to cover material cost and labor. If your order hasn't been started you will receive a full refund.
-Due to monitor settings, colors may appear slightly different on your computer than they do in person. Due to this, we will not exchange or issue a refund if we gave you the correct colored items you selected. We are not liable for the fur texture being different than what you had envisioned. The same fur from the same supplier can vary batch to batch so we can also not guarantee that ordering the same fur at a later date will guarantee a 100% match.
Can I return or exchange an item(s)?
- Returns and exchanges are accepted on a case by case basis. Returned items MUST be returned in unused condition. When we receive the items we will contact you regarding the refund.
-If you ordered wrong or changed your mind,we may offer to exchange the items. Products must be unworn and with original packaging.
-If the product(s) received matched the products in your order, then you will be responsible for the cost to ship it back.
-If we made an error resulting in you needing to send the items back, we will reimburse you for the shipping via Paypal store credit only. We will not pay courier fees or express fees. We will only pay for tracked packet, or standard with a local postal service (ie. CanadaPost, USPS)
- If the product(s) received matches the products in your order and you are unsatisfied with the quality, you will pay for the shipping to us. If we receive the item and deem it is not of quality, we will then reimburse the shipping you paid.
If you have any further questions or concerns please email us BEFORE ordering at firstname.lastname@example.com


text:
Can only see posts on Facebook page if I am logged in
Hi there
I have installed the plugin successfully and it is all working fine, but the problem is now, that it only shows the post on the fan page when we I am logged in as myself. If I login in as someone else or if I am logged out and visit the fan page, the post doesn't appear.
Is there some setting that I am missing?
I am an administrator on the page (ie it is not directly linked to my profile – I have access to make changes etc) but there are lots of people who will be posting on the blog and who are administrators like me where we want those posts added. Does it only work if you are the page owner?
Would be really glad of any advice you can give.
Many thanks in advance.
- The topic 'Can only see posts on Facebook page if I am logged in' is closed to new replies.


text:
Artist: Joseph-Antoine Romagnési (French, Paris ca. 1782–1852 Paris)
Date: 1811
Culture: French
Medium: Relief: plaster, painted to resemble yellowish stone; frame: green marbleized wood
Dimensions: 45 1/2 × 29 in. (115.6 × 73.7 cm)
Classification: Sculpture
Credit Line: Rogers Fund, 1927
Accession Number: 27.191.2
This is the original plaster for a relief intended to celebrate the birth of Napoleon I's son, Napoleon II, or François-Charles-Joseph, in 1811, who was endowed by his father with the title King of Rome in symbolic confirmation of the imperial dynasty. The work was exhibited at the Salon of 1812. Its formal aspects were possibly inspired by Roman reliefs in the Palazzo Spada, Rome. A smaller plaster relief depicting the King of Rome with the she-wolf who suckled Romulus and Remus also exists. Due to the Bourbon Restoration of 1814, the marble version was never completed; the marble block was instead used for Romagnési's variant composition of 1817, Minerva Protecting France.


text:
i'm a girl, almost eighteen and I've never had a boyfreind or kissed anyone, is that really weird?
Most Helpful Guy
I am 18 and have never even hugged a girl, let alone kissed or got involved with one. You're much better off waiting for the right person than getting with anyone just for the sake of it; I know that if or when I kiss a girl or get a girlfriend I want it to be with someone special to me that I really feel for rather than just whoever is desparate enough.00|00|0


text:
We already treated you to some precursive benchmark results that hinted at how the Galaxy Note 4 might fare against some of its rivals performance-wise, but what about its innovative peer, the Galaxy Note Edge? The most notable difference between the Note 4 and the Edge is, ostensibly, the overlapping, YOUM-like sloped screen of the latter, which doubles as a separate auxiliary display.
As we know, both the Edge and the Note 4 come with the same, power-laden SoC, i.e. a quad-core Qualcomm Snapdragon 805, churning its gears at 2.7GHz. Paired with an Adreno 420 graphics-handling silicon, the Galaxy Note Edge has to power a pixel-dense Quad HD display, which normally takes its toll on the overall performance. That said, it was not surprising that the benchmark tests of the Galaxy Note 4 showed that it's comparable with older flagship smartphones, such as the HTC One (M8) and the Samsung Galaxy S5 (which are equipped with an older iteration of the Snapdragon goodness).
So, is the Galaxy Note Edge akin to the Note 4 performance-wise? Sound logic suggests that this is so, and fortunately, we were able to lay our hands on a Galaxy Note Edge at IFA 2014. Of course, being the geeks we are, we run some synthetic benchmark tests on it and see how it fares against the other in GFXBench and Vellamo. However, take into consideration that the device we procured benchmark tryouts on was an early pre-production unit and things might change a bit once the Galaxy Note Edge hits the shelves.
Vellamo Metal
Higher is better
GFXBench T-Rex HD on-screen
Higher is better
GFXBench Manhattan on-screen
Higher is better


text:
What is JotForm?
JotForm is a free online form builder which helps you create online forms without writing a single line of code. No sign-up required.
At JotForm, we want to make sure that you're getting the online form builder help that you need. Our friendly customer support team is available 24/7.
We believe that if one user has a question, there could be more users who may have the same question. This is why many of our support forum threads are public and available to be searched and viewed. If you'd like help immediately, feel free to search for a similar question, or submit your question or concern.
Zoho CRM Integration: Not sending submitted data in some fields to Zoho.Asked by rvselect1234 on February 16, 2016 at 10:33 AM
For some reason I've been able to integrate my two forms with Zoho CRM, but only a few select leads are filtering through. I've redone the integration multiple times and still no luck.
JotForm Support
I'm not sure if I understand your query correctly. Do you mean to say that the form submissions are not creating leads in Zoho or are you experiencing any issue while integrating Zoho with your JotForm? Could you provide us with more information on the issue so that we can guide you in the right direction? It would be helpful if you can also provide us with the screenshot of the issue.
We will wait for your response. Thank you!
Integration is complete but the form submissions are not creating leads in Zoho. Except for a couple. For example, we've received multiple form submissions from jotforms but only one lead has been created in Zoho CRM today.
JotForm Support
I think this is the form you are referring to: http://www.jotformpro.com/form/52795765836979
The problem might related due to the field mapping. I see that you are using a single TextBox field for the Name field, try replacing it with the "Full Name" field instead, which if found under Quick Tools, it should work best with your integration.
Let us know if you need more help.
Okay, I've updated the field to be 'Full Name' and remapped all my integrations to include this. I'll see if it starts to work.
Unfortunately leads are still not filtering through.
JotForm Support
I've cloned your form and was able to submit leads to Zoho CRM. Please try switching your tabs to "All Open Leads" in Zoho. See if all leads are there. Or, try checking Unread Leads.
I checked all categories, including All Open Leads and I have the same two leads sitting in there.
JotForm Support
Please allow some time to run few tests in this regard and get back to you with relevant information. In the meantime, could you check if it happens with creating a new contact instead of a lead?
We will wait for your response. Thank you!
JotForm Support
Thank you for sharing your findings through Zapier. Let me get back to you once I complete my tests with Zoho integration. The other question is moved to a separate thread and shall be addressed there shortly.
Thank you!
If mandatory fields are missing record will not be created
JotForm Developer
Alternatively, if you are experiencing some problems on the Zoho integration you can try to import your data using the CSV, XLS file formats. Firstly, you need to get the CSV or XLS format of your submissions on JotForm. Please, check the guide from the link below:
Then, follow the instructions which need to be done on ZOHO CRM,
Please, try this one and let us know the results.
Hi, I have imported leads in the past but I need to integrate in order to receive leads on an ongoing basis throughout the day from Jotform.
JotForm Support
I understand. As I tested the integration with my account on my form, I see that the submissions are coming through to the leads without any issues. As I check your JotForm now, I see that Zoho CRM is not integrated to it. I think you must have removed it since you are using Zapier. Could you check if the Zoho integration works properly by using the authentication token method instead of username.
You may generate the Authentication token by using the link below while you are logged into your Zoho account.
Also, please make sure that you are selecting the required fields from Zoho to map with the form fields.
Please let us know if we can be of any further help. We will be happy to assist.
I re-establish the integration and everything seems to be working...except one field does not seem to be migrating over, even though the exact same field in the other form (there are two) migrates over fine. I deleted and reintegrated a few times for this form, but still no field coming through. Any ideas?
JotForm Developer
Please, check the related field on the ZOHO integration wizard. It may be forgotten when you set the integration. Please, see it from the below:
After checking the field's availability on the wizard, please do let us know the results.
Here is a screenshot of the integration. The field missing is 'No of Employees', aka 'RV Year'. Seems to be added and integration fine on the backend.
JotForm Support
I cloned your form and I was able to see the issue, as the field "No. of Employees" is numeric I tried to allow only numeric values in the cloned form of yours, it did not work.
I decided to create a new form and integrate it with Zoho, added a numeric field named "No. of Employees" in my form and still it was not sent to Zoho.
I will escalate it to our second level, you will receive news about it soon.
Thank you!!
Hi, can you advise if there is any update on this?
There are no updates on this at this time, but as soon as there are any our developers will let you know about the same through this thread.
JotForm Support
Apologies for the late update, but we'd like to let you know that this has been fixed. Number of employees field will now be sent properly to ZohoCRM.
Please do inform us if there is anything else w can help you with.


text:
Heber City • In the spring of 2009, Lon Kennard Sr., now 70, was walking on air, having been recognized for his work in Ethiopia, where he and his wife, DeAnna, established an orphanage for troubled and abandoned children. The Wasatch County couple also had adopted six Ethiopian children.
Wednesday, the humanitarian and former LDS bishop was sentenced to three terms of five years to life in prison to be served consecutively. He had earlier pleaded guilty to three first-degree felony counts of aggravated sex abuse of a child.
In March 2010, he was charged with 43 felony counts of sex abuse and sexual exploitation of a child. He has been held in the Wasatch County jail since that time.


text:
150 N. Michigan Ave. Ste. 1420
Chicago, IL 60601
- (312) 263-6477
- (312) 263-7682
- email@example.com
150 N. Michigan Ave. Ste. 1420
Chicago, IL 60601
Practice emphasizes Traditional Client Representation and Litigation, as well as serving as a Certified Mediator.
The American University, Washington College of Law, JD - 1985
The Pennsylvania State University, BA (Political Science), BA (Religious Studies) - 1982
Legal Organizations
Editor, Virginia Family Law Quarterly (2014 to present), Certified Family Mediator (2012 to present), Virginia State Bar, Family Law Section Board of Governors, 2002-08, Chair, 2006-07; Frequent lecturer in Virginia Family Law and Mediation, Virginia State Bar Disciplinary Committee; Fairfax County Bar Association; Loudoun County Bar Association; Commissioner in Chancery; Neutral Case Evaluator; Motions Day Conciliator.
Washingtonian Top Lawyers, Best Lawyers in America; Northern Virginia Magaizine. Top Lawyers; Virginia Business Magazine, Legal Elite.
CLE Presentations
Family Law Legislative and Case Law Update (October 2016, Fairfax Bar Association); Trial Preparation and Presentation of Child Custody Cases, (January 2016, Northern Virginia Pro Bono Center); Difficult Clients and Counsel in High Conflict Cases: Being Ethical and Effective (October 2015, Virginia Continuing Legal Ed. Foundation); Navigating the High Conflict Divorce (October 2014, Virginia Continuing Legal Ed. Foundation); Getting to Yes (June 2014, Fairfax Bar Association, Alternative Dispute Resolution Section); Everything You Wanted to Know About Child Support (September 2013, Virginia Trial Lawyers Association); Examining the Trend Toward Shared Custody (April 2011, Virginia Continuing Legal Ed. Foundation); Divorce, Foreclosure and Bankruptcy (April 2011, Virginia Continuing Legal Ed. Foundation); Practicing Family Law at the Intersection of Divorce and Religion (October, 2010, Virginia Women Attorneys Assoc., and December 2010, Fairfax Bar Association); Anatomy of a Spousal Support Hearing (March, 2010, Virginia Trial Lawyers Assoc.); Spousal Support Trial Strategies (September 2009, Fairfax Bar Association); Equitable Distribution in a Recession (April 2009, Virginia Continuing Legal Ed. Foundation); Evidentiary Issues and Objections in Family Law Cases (October 2008, Virginia Continuing Legal Ed. Foundation); 23rd Annual Advanced Family Law Seminar, Moderator (April 2007, Virginia Continuing Legal Ed. Foundation); The Evolving Role of Fault in Virginia (with Patrick McConnell) (April 2006, Virginia Continuing Legal Ed. Foundation); Ethical Concerns in Dealing with Difficult Clients and Opposing Counsel (May 2005, Virginia Continuing Legal Ed. Foundation); So You Thought You Could Avoid Family Law (November 2004, Virginia State Bar); Family Law Discovery (May 2004, Virginia Continuing Legal Ed. Foundation); Managing Equitable Distribution Cases (July 2003, Half Moon Enterprises); Relocation Custody Cases (April 2002, Fairfax Bar Association) Division of Stock Options in Divorce (June 2001, Fairfax Bar Association); Rehabilitative Alimony (May 2000, Fairfax Bar Association)
Family Law News, "Monitoring Mediation: Identifying and Monitoring Uncertified Mediators in Virginia," Vol. 23, No. 3, 2003 and "A New Tool for the Divorce Lawyer: Using the Attorney Lien to Get Paid," Vol. 26, No. 3, 2006; The Virginia Lawyer, "You Bet Your Spouse's Life: Examining Virginia's Position on Life Insurance in Divorce," Vol. 53, No. 7, 2005; Assessing "Manifest Injustice" in Spousal Support Cases: Playing the Blame Game, Vol.55, No. 7, 2007, Evaluative Mediation: Friend or Foe, Resolutions, Office of the Executive Secretary of the Virginia Supreme Court, Dept. of Judicial Services, Division of Dispute Resolution, Volume 25, Issue 5 (2016).


text:
The AFC North is an interesting division that possess two top fantasy QB's, two others with potential, and while Carson Palmer is probably the best of the bunch, at this point, Big Ben gets the nod.
Roethlisberger will enter his sixth full season in the league as the proud owner of two Super Bowl rings after his Steelers defeated the Cardinals in Super Bowl XLIII.
In 2008, he threw for over 3,300 yards with 19 total TDs, two coming via the run.
This year, the same cast of characters are back, but Santonio Holmes is a year older and more dangerous. Big Ben's offensive weapons remain intact and strong.
Look for 3,500 yards and between 23 to 26 TDs.
Palmer is the most talented QB in the division stuck on a horrible team. When healthy, he's right there in the conversation with Manning, Brady and Brees.
Last year, a lingering elbow injury forced him to miss 12 games.
After an off season to strengthen his elbow, Palmer is healthy, and Ochocinco looks rearing to go.
Mix that in with some of the younger receivers and look for a nice comeback season. He will get over 3,500 yards with 20—25TDs.
3. Joe Flacco
For most of his rookie season, he wasn't called upon to do much, aside from managing the offense and not making mistakes. But towards the end, as Flacco's confidence grew, OC Cam Cameron opened up the playbook ever so slightly and he produced, finishing with just under 3,000 yards and 16 total TDs, two coming via the run.
While this will still be a team that relies on its running game and defense to win games, look for another step forward in year two with over 3,000 yards and between 18 to 20 TDs.
Brady Quinn could certainly end up as the starter, and if so, our projections wouldn't differ too drastically, but our thinking is that Anderson's the better QB, and his problems last year were due to a horrendous offensive unit and the incessant drops by WR Braylon Edwards in crucial situations.
The forecast in the Dawg Pound isn't very bright this season as the team dealt TE Winslow to the Bucs and WR Stallworth is suspended indefinitely.
Regardless, look for a team that relies heavily on the run and for Anderson, or Quinn, to throw for 2,500 - 2,700 yards with 15-18 TDs.
Draft Tip
Roethlisberger will probably be selected before Palmer. His name will be called from round four on.
Palmer, coming off a serious injury, will probably last until round six, and could potentially be an excellent fantasy sleeper.
Flacco will be available after round ten and you should be able to scoop up Anderson or Quinn at the end of the draft.
source: www.profootball101.org


text:
The Plantation Lodge Reviews
Read what our previous clients thought of The Plantation LodgeClient Score: 4.5 Showing 1 - 4 of 4 reviews
The Plantation Lodge
Phillip & Linda Carling4
Great rooms , spacious and clean . Food good and the picnic lunches excellent ) complete with tablecloths !!)!brilliant guide Barack !Read full trip review
The Plantation Lodge
Beautiful place, found it a little stuffy and a bit too formalRead full trip review
The Plantation Lodge
Diane & Paul Riva4
The grounds were beautiful. The room was very good as well. The dinner's were particularly noteworthy because of the high quality and well prepared food.Read full trip review
The Plantation Lodge
Emmet O'Brien5
A fantastic base to explore the caldera of Ngorongoro and lake Manyara. The lodge had a colonial feel to it, the facilities were again excellent and we looked forward to the meals every night after a long day out on safari.Read full trip review


text:
October 09, 2016
We are beta testing a new live view. Our new software adds count data to the image. We are also providing graphical data of the last 24 hour period. Further data wil be available to subscribers in the near future.
Please let us know if you like the changes we are making to this site.
Have fun,


text:
- Trending Now: More Trending:
- syzygy hegemon repugnant white nationalist, white supremacist bereft
give one's all
Definition of give one's all
: to do or give as much as one can to achieve something, to support a cause, etc. He gave his all for the cause. You'll never succeed in this business unless you give (it) your all.
Word by Word Definitions
: to make a present of
: to grant or bestow by formal action
: to accord or yield to another
: capacity or tendency to yield to force or strain : flexibility
: the ability of a material to bend or stretch
: the whole amount, quantity, or extent of
: as much as possible
: every member or individual component of
: wholly, quite
: only, exclusively
: just
: the whole number, quantity, or amount : totality
: used in such phrases as for all I know, for all I care, and for all the good it does to indicate a lack of knowledge, interest, or effectiveness
: everybody, everything
: the whole of one's possessions, resources, or energy
Seen and Heard
What made you want to look up give one's all? Please tell us where you read or heard it (including the quote, if possible).


text:
Free three column Violin wordpress theme. adsense ready and widget ready. very nice layout and fully customizable with a right sidebar. Lots of extras and easy navigating from tabs on the top of the page.
* 3 columns
* Grey & Orange
* Adsense ready
* Valid XHTML and CSS Tested on the following browsers:
IE6, IE7, FireFox 2, Opera and Safari
Theme Demo ||wordpress Download
Author Buy Tents
Similar Posts:
- Violin
- Red Business
- Sun Flowers
- Grey Business Theme
- Dark Business Theme
- Uncomplicated Red
- Transformers
- Anime Girl
- Clone Wars
- Roulette Wheel
Popularity: 4% web directory software
Leave a Reply
You must be logged in to post a comment.


text: This week the gang is back in the garage after a short hiatus and steps in a big, steaming pile of Star Wars. Josh picks up his third copy of GTAV, Jay rocks out to the announcement of Rock Band 4, and Rowan gets his MOBA on with Heroes of the Storm. Plus, Bloodborne, Guitar Hero Live, Pillars of Eternity, charging for Steam mods, the Bobas Fett, and more!


text:
Hockey players are used to playing in frigid conditions, but the following has got to cold, even for them.
Several Arizona Coyotes players have started doing the "Ice Bucket Challenge," which raises awareness for ALS (Lou Gehrig's Disease).
Basically, a player gets challenged to dump a bucket full of ice and water on his head, and then he "pays it forward" by encouraging others to do it.
A video on the Coyotes' website shows center Antoine Vermette taking the challenge, and after he completes it, he calls out a few teammates — including defenseman Keith Yandle — to do the same.
Yandle is shown accepting the challenge, and he ups the ante with three ice buckets, even pouring a smaller pail on a small girl, possibly his daughter, at the end. Yandle, too, calls out a handful of people to do the challenge, including left wing Paul Bissonnette.
- Horizon's Kody Huff more than a rising baseball star
- Campo Verde's Kanani Hiapo thrives on volleyball court, in the classroom
- Raymond S. Kellis sophomore Chase Weaver balances leadership roles in sports, church
- Westwood's Brianna Anderson makes big differences with little actions
- Marcos de Niza kicker Krysten Muir using football success to build up others
- Arcadia High School's Grant Loftin leads in lacrosse and beyond
- Williams Field High School junior Lindsay O'Driscoll finds time to help others
- Scottsdale Christian's Christina Clark has dreams, reality of helping others
- Golf, piloting and helping others are Brody Burnell's passions
- Teddy bear drive, speeches help Emery Miller inspire children to overcome adversity